We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.39 | 1.30% | 30.48 | 30.40 | 30.50 | 30.52 | 30.31 | 30.32 | 1,121,708 | 21:15:26 |
From May 2021 to May 2024
By Kosaku Narioka
Chugai Pharmaceutical Co. obtained regulatory approval in Japan for a Covid-19 antibody cocktail created by Regeneron Pharmaceuticals Inc.
The Japanese unit of Swiss drug maker Roche Holding AG said Monday that the antibody cocktail, Ronapreve, was approved to treat mild to moderate Covid-19 patients.
Regeneron and Roche agreed to jointly manufacture, develop and distribute the antibody cocktail.
Chugai said it had reached an agreement with the Japanese government to secure domestic supply of the antibody cocktail for 2021.
Chugai said Ronapreve hasn't yet been approved in countries other than Japan.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
July 19, 2021 21:51 ET (01:51 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
